Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
Open Access
- 20 December 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1), e000266
- https://doi.org/10.1136/jitc-2019-000266
Abstract
Background The use of checkpoint inhibitors has revolutionized cancer therapy. Unfortunately, these therapies often cause immune-related adverse effects, largely due to a lack of tumor specificity. Methods We stained human natural killer cells using fusion proteins composed of the extracellular portion of various tumor markers fused to the Fc portion of human IgG1, and identified Nectin4 as a novel TIGIT ligand. Next, we generated a novel Nectin4 blocking antibody and demonstrated its efficacy as a checkpoint inhibitor in killing assays and in vivo. Results We identify Nectin4 to be a novel ligand of TIGIT. We showed that, as opposed to all other known TIGIT ligands, which bind also additional receptors, Nectin4 interacts only with TIGIT. We show that the TIGIT-Nectin4 interaction inhibits natural killer cell activity, a critical part of the innate immune response. Finally, we developed blocking Nectin4 antibodies and demonstrated that they enhance tumor killing in vitro and in vivo. Conclusion We discovered that Nectin4 is a novel ligand for TIGIT and demonstrated that specific antibodies against it enhance tumor cell killing in vitro and in vivo. Since Nectin4 is expressed almost exclusively on tumor cells, our Nectin4-blocking antibodies represent a combination of cancer specificity and immune checkpoint activity, which may prove more effective and safe for cancer immunotherapy.Keywords
Funding Information
- Israel Science Foundation (24/7)
This publication has 24 references indexed in Scilit:
- Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer ModelsCancer Research, 2016
- PILRα binds an unknown receptor expressed primarily on CD56bright and decidual-NK cells and activates NK cell functionsOncotarget, 2016
- Identification of CD112R as a novel checkpoint for human T cellsThe Journal of Experimental Medicine, 2016
- Dynamic Co-evolution of Host and Pathogen: HCMV Downregulates the Prevalent Allele MICA∗008 to Escape Elimination by NK CellsCell Reports, 2015
- DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival informationCell Death & Disease, 2014
- Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.2013
- BioProfiling.de: analytical web portal for high-throughput cell biologyNucleic Acids Research, 2011
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2009
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cellsNature Immunology, 2008
- Determination of subcutaneous tumor size in athymic (nude) miceCancer Chemotherapy and Pharmacology, 1989